^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD5863

    i
    Other names: HBM 7022, AZD5863, HBM7022, AZD-5863, HBM-7022, AZD 5863
    Company:
    AstraZeneca, Harbour BioMed
    Drug class:
    CD3 agonist, CLDN18.2 inhibitor
    Related drugs:
    2ms
    D9750C00001: Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=280, Recruiting, AstraZeneca | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive • CLDN1 positive
    |
    AZD5863
    4ms
    An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. (PubMed, J Immunother Cancer)
    AZD5863 mediates potent anti-tumor activity in vitro and in vivo, while inducing limited levels of cytokines. This work improves our understanding of the mechanism of action of affinity balanced TCEs and informs the design of a phase 1 trial testing AZD5863 in gastric, pancreatic, and esophageal adenocarcinoma (NCT06005493).
    Journal
    |
    CLDN18 (Claudin 18) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • FASLG (Fas ligand)
    |
    AZD5863
    over2years
    Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, AstraZeneca
    New P1/2 trial • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    AZD5863